{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '1.', 'INTRODUCTION', '1.1.', 'Background Information', 'Myasthenia gravis (MG) is an autoimmune disorder characterized in most cases by T-cell', 'and antibody responses to neuromuscular junction proteins such as skeletal muscle nicotinic', 'acetylcholine receptor (AChR). Antibodies against epitopes of the AChR of the', 'neuromuscular junction cause failure of neuromuscular transmission, resulting in the', 'characteristic fatigue and weakness associated with this severe disorder. The muscle', 'weakness fluctuates with activity, and periods of rest offer only a temporary reprieve', '(Howard, Barohn et al. 2013).', 'Autoimmune MG has a reported worldwide prevalence of 40-180 per million people and an', 'annual incidence of 4-12 per million people. Overall, MG incidence and prevalence shows', 'little geographic variation (Gilhus and Verschuuren 2015).', 'Autoimmune MG is characterized by the presence of antibodies against several components', 'of the neuromuscular junctions. The most common antibody found in autoimmune MG is', 'directed against post-synaptic AChRs. Anti-AChR antibodies are present in approximately', '80% of all autoimmune MG patients. Less frequent autoantibodies found in autoimmune MG', 'include the anti-muscle-specific kinase (MuSK) antibody (4% of the cases) and the anti-', 'lipoprotein receptor-related protein-4 (LRP4) antibody (2% of the cases) directed against', 'LPR4. All these autoantibodies belong to the immunoglobulin G (IgG) class (Gilhus and', 'Verschuuren 2015; Gilhus 2016).', 'In approximately 5-20% of the MG patients, no serum antibodies against neuromuscular', 'junction proteins can be detected (Vincent, Lang et al. 2006; Kaminski 2016). Although in', 'some seronegative MG patients the disease may not be mediated by antibodies, in other cases', 'the (apparent) absence of specific autoantibodies in patients may be due to insufficient', 'sensitivity of the assay. Indeed, one third of MG patients, who are seronegative on standard', 'testing, are seropositive on cell-based testing. The seronegative group probably includes', 'some patients with anti-AChR, -MuSK or -LRP4 antibodies that are not detected because of', 'insufficient test sensitivity (Gilhus 2016).', 'The treatment of MG is based on a variety of medications and medical procedures used either', 'alone or in combination (see Section 1.3).', 'Given the pathogenic role of autoantibodies in MG, a possible novel therapeutic approach to', 'this disease may include the use of drugs that lower the level of pathogenic autoantibodies', 'rapidly and sustainably. Since all the specific autoantibodies found in MG belong to the IgG', 'isotype, agents that specifically lower the level of these antibodies without affecting the level', 'of other isotypes such as IgA, IgE and IgM may be of special interest.', 'argenx BVBA', 'Confidential', 'Page 43 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'One such strategy involves inhibition of the neonatal Fc receptor (FcRn). FcRn was shown to', 'play a central role in trafficking IgGs and albumin into recycling pathways rescuing them', 'from lysosomal degradation. Molecules that block the interaction of FcRn with IgGs are', 'expected to induce degradation and fast clearance of pathogenic IgGs leading to a lowering', 'of their serum level (Roopenian and Akilesh 2007; Challa, Velmurugan et al. 2014).', 'Thus, targeting the FcRn-IgG interaction would be a rational therapeutic approach to rapidly', 'clear pathogenic autoantibodies in IgG-driven autoimmune diseases such as MG.', '1.2.', 'Investigational Medicinal Product', 'ARGX-113 is a human IgG1-derived Fc fragment of the za allotype that binds with', 'nanomolar affinity to human FcRn. ARGX-113 encompasses IgG1 residues D220-K447 (EU', 'numbering scheme) and has been modified with the so-called ABDEGTM technology', '(ABDEGTM = antibody that enhances IgG degradation) (Vaccaro, Zhou et al. 2005) to', 'increase its affinity for FcRn at both physiological and acidic pH. The increased affinity for', 'FcRn of ARGX-113 at both acidic and physiological pH results in a constitutively blockage', 'of FcRn-mediated recycling of IgGs.', 'Given the essential role of the FcRn receptor in IgG homeostasis, inhibiting this FcRn', 'function, as achieved by ARGX-113, leads to rapid degradation of IgGs, which is expected to', 'include autoantibodies in IgG-driven autoimmune diseases.', 'This concept has been validated in various murine disease models together with', 'pharmacokinetic/pharmacodynamio (PK/PD) studies in cynomolgus monkeys, either by', 'using ARGX-113 or a full-length mAb analogue (HEL-ABDEGTM) (Patel, Puig-Canto et al.', '2011; Challa, Bussmeyer et al. 2013).', 'The antibody clearing properties of ARGX-113 were confirmed in PK/PD studies in', 'cynomolgus monkeys. A single infusion of ARGX-113 resulted in a decrease of IgG up to', '55% without altering serum albumin concentrations nor IgM or IgA levels. This PD effect as', 'measured with a tracer IgG molecule was proven to be more potent than intravenous', 'immunoglobulin (IVIg), both in rapidity of onset as in depth of the effect. Repeated dosing', 'could improve the PD effect up to a maximum IgG reduction of 75%.', 'These nonclinical data validated the further development of ARGX-113 for assessing its', 'therapeutic potential in IgG driven autoimmune indications.', 'To date, a Phase 1 (ARGX-113-1501) and a Phase 2 (ARGX-113-1602) trial are completed', 'as part of the clinical development of ARGX-113 for the treatment of generalized myasthenia', 'gravis (gMG).', 'ARGX-113-1501 was a randomized, double-blind, placebo-controlled, First-in-Human (FIH)', 'Phase 1 trial conducted in 62 healthy volunteers to assess the safety and tolerability and to', 'evaluate the PK and PD characteristics of single and multiple ascending intravenous (IV)', 'doses of ARGX-113. The trial showed that a single administration of ARGX-113 reduced', 'argenx BVBA', 'Confidential', 'Page 44 of 110']\n\n###\n\n", "completion": "END"}